DK0975668T3 - Modificerede TNFa-molekyler, DNA, der koder for sådanne modificerede TNFa-molekyler og vacciner omfattende sådanne modificerede TNFa-molekyler og DNA - Google Patents

Modificerede TNFa-molekyler, DNA, der koder for sådanne modificerede TNFa-molekyler og vacciner omfattende sådanne modificerede TNFa-molekyler og DNA

Info

Publication number
DK0975668T3
DK0975668T3 DK98916866T DK98916866T DK0975668T3 DK 0975668 T3 DK0975668 T3 DK 0975668T3 DK 98916866 T DK98916866 T DK 98916866T DK 98916866 T DK98916866 T DK 98916866T DK 0975668 T3 DK0975668 T3 DK 0975668T3
Authority
DK
Denmark
Prior art keywords
tnfα molecules
modified tnfα
dna
modified
molecules
Prior art date
Application number
DK98916866T
Other languages
Danish (da)
English (en)
Inventor
Martin Roland Jensen
Iben Dalum
Soren Mouritsen
Henrik Elsner
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Application granted granted Critical
Publication of DK0975668T3 publication Critical patent/DK0975668T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98916866T 1997-04-15 1998-04-15 Modificerede TNFa-molekyler, DNA, der koder for sådanne modificerede TNFa-molekyler og vacciner omfattende sådanne modificerede TNFa-molekyler og DNA DK0975668T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
EP98916866A EP0975668B1 (en) 1997-04-15 1998-04-15 MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA

Publications (1)

Publication Number Publication Date
DK0975668T3 true DK0975668T3 (da) 2006-09-25

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98916866T DK0975668T3 (da) 1997-04-15 1998-04-15 Modificerede TNFa-molekyler, DNA, der koder for sådanne modificerede TNFa-molekyler og vacciner omfattende sådanne modificerede TNFa-molekyler og DNA

Country Status (29)

Country Link
US (1) US7118750B1 (enExample)
EP (1) EP0975668B1 (enExample)
JP (1) JP2001521386A (enExample)
KR (1) KR100522289B1 (enExample)
CN (1) CN1178955C (enExample)
AR (1) AR012427A1 (enExample)
AT (1) ATE326481T1 (enExample)
AU (1) AU743400B2 (enExample)
BR (1) BR9811462A (enExample)
CA (1) CA2289476A1 (enExample)
CZ (1) CZ9903657A3 (enExample)
DE (1) DE69834556T2 (enExample)
DK (1) DK0975668T3 (enExample)
EE (1) EE9900461A (enExample)
ES (1) ES2264569T3 (enExample)
HR (1) HRP980203B1 (enExample)
HU (1) HUP0001930A3 (enExample)
IL (1) IL132281A0 (enExample)
NO (1) NO995002L (enExample)
NZ (1) NZ337955A (enExample)
PL (1) PL194221B1 (enExample)
RU (1) RU2241715C2 (enExample)
SI (1) SI0975668T1 (enExample)
SK (1) SK285639B6 (enExample)
TR (1) TR199902562T2 (enExample)
TW (1) TW510921B (enExample)
UA (1) UA72440C2 (enExample)
WO (1) WO1998046642A1 (enExample)
ZA (1) ZA983148B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
PT1159003E (pt) * 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
AU2001265830A1 (en) * 2000-06-21 2002-01-02 Ferring, B.V. Solubilised protein vaccines
AU2003208314A1 (en) * 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
WO2005084198A2 (en) 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2648746A1 (en) 2010-12-08 2013-10-16 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
WO2016179430A1 (en) 2015-05-05 2016-11-10 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251037B1 (en) * 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
HK1022918A1 (en) 2000-08-25
ATE326481T1 (de) 2006-06-15
EP0975668B1 (en) 2006-05-17
TR199902562T2 (xx) 2000-02-21
DE69834556D1 (de) 2006-06-22
PL194221B1 (pl) 2007-05-31
CN1252809A (zh) 2000-05-10
BR9811462A (pt) 2000-09-12
NO995002L (no) 1999-12-15
KR20010006416A (ko) 2001-01-26
IL132281A0 (en) 2001-03-19
NZ337955A (en) 2000-09-29
DE69834556T2 (de) 2007-05-10
HUP0001930A2 (hu) 2000-09-28
NO995002D0 (no) 1999-10-14
ES2264569T3 (es) 2007-01-01
EP0975668A1 (en) 2000-02-02
RU2241715C2 (ru) 2004-12-10
CN1178955C (zh) 2004-12-08
PL336295A1 (en) 2000-06-19
SK140999A3 (en) 2000-06-12
JP2001521386A (ja) 2001-11-06
AR012427A1 (es) 2000-10-18
HRP980203B1 (en) 2003-04-30
US7118750B1 (en) 2006-10-10
KR100522289B1 (ko) 2005-10-19
HUP0001930A3 (en) 2001-10-29
AU7030398A (en) 1998-11-11
WO1998046642A1 (en) 1998-10-22
UA72440C2 (en) 2005-03-15
TW510921B (en) 2002-11-21
HRP980203A2 (en) 1998-12-31
SK285639B6 (sk) 2007-05-03
AU743400B2 (en) 2002-01-24
CA2289476A1 (en) 1998-10-22
CZ9903657A3 (cs) 2001-09-12
EE9900461A (et) 2000-06-15
ZA983148B (en) 1999-10-15
SI0975668T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
EE9900461A (et) Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid
DK2233498T3 (da) Kallikrein-inhiberende Kunitz-domæneproteiner og nukleinsyrer, der koder for disse
EP0973372A4 (en) VITICOLE EQUIPMENT, AND SYSTEM AND METHOD FOR MECHANIZING VITICULTURE
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
IS5525A (is) Innúðabúnaður og aðferð
NO20016243D0 (no) Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
DK1490386T3 (da) Nyt polypeptid og nukleinsyrer kodende for dette
DE69533634D1 (de) Geranylgeranyldiphosphate-Synthase und diese kodierende DNA
EP0964930A4 (en) CATALYTIC RNA MOLECULES
FI962247A7 (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden kä yttömenetelmät
DE69718600D1 (de) Polyether-Nukleinsäuren
DK1071767T3 (da) Gen, der koder for heliomicin, og anvendelse heraf
NO20001552L (no) Katalysator og fremgangsmÕter hvor slike benyttes
FR2776928B1 (fr) Vaccins adn adjuves
DK1228193T3 (da) Felint calicivirirus-gener og rekombinante vacciner der indeholder dem
DK1003383T3 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
ID19836A (id) Metoda dan apparatus pengkodean dan pemecahan-kode data digit
EP1001964A4 (en) TANGO-78, TANGO-79 AND TANGO-81 NUCLEIC ACID MOLECULES
EP1047773A4 (en) CUBILIN PROTEIN, DNA SEQUENCES ENCODING CUBILIN AND THEIR USE
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
NL1010171A1 (nl) Reed-Solomon decoderingsinrichting en decoderingswerkwijze.
NO20003268L (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
NO306963B1 (no) Identifikasjonssystem basert på strekkoder og spesielt tilpasset boreroer
EP1409683A4 (en) HELICOBACTER PROTEINS, NUCLEIC ACIDS AND THEIR USE